The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Linvention concerne des vaccins anticancéreux à base dacide ribonucléique (ARN), ainsi que des méthodes dutilisation des vaccins et des compositions comprenant les vaccins.